Takeda's ixazomib meets PFS endpoint in myeloma study

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said an interim analysis of the Phase

Read the full 125 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE